{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:03:24Z","timestamp":1789517004064,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T00:00:00Z","timestamp":1656115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["842002001"],"award-info":[{"award-number":["842002001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Advanced pulmonary sarcoidosis causes significant morbidity and can lead to death. Large trials demonstrated efficacy of antifibrotics in patients with progressive fibrosing interstitial lung diseases (PF-ILD), including a few with sarcoidosis. To date, little is known about this progressive fibrosing phenotype in sarcoidosis. Diffusion capacity of carbon monoxide (DLCO) may be a useful functional marker to screen for advanced pulmonary sarcoidosis. In this study, we describe a cohort with advanced pulmonary sarcoidosis and we gain insights in the progressive fibrosing phenotype in sarcoidosis.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with sarcoidosis and a DLCO\u2009&lt;\u200950% predicted were included in this retrospective cohort study. First measurement of DLCO\u2009&lt;\u200950% predicted was the baseline. Lung function data, HRCT, pulmonary hypertension (PH) and mortality were collected. Patients with\u2009&gt;\u200910% fibrosis on HRCT meeting the criteria for ILD-progression within 24\u00a0months were labelled as PF-ILD. With Cox-regression analysis predictors of mortality were established.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>106 patients with a DLCO\u2009&lt;\u200950% predicted were included. Evolution of forced vital capacity (FVC) varied widely between patients from \u2212\u00a034% to\u2009+\u200945% after 2\u00a0years follow-up, whereas change in DLCO varied between \u2212\u00a011% and\u2009+\u200926%. Fourteen patients (15%) met the PF-ILD criteria, of whom 6 (43%) died within 10\u00a0years versus 10 (13%) in the non PF-ILD group (p\u2009=\u20090.006). PH was present 12 (11%), 56 (53%) demonstrated\u2009&gt;\u200910% fibrosis on HRCT. Independent predictors of mortality and lung transplantation in the whole cohort are PH, PF-ILD and UIP-like pattern.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, within this group with advanced pulmonary sarcoidosis disease course varied widely from great functional improvement to death. PF-ILD patients had higher mortality rate than the mortality in the overall pulmonary sarcoidosis group. Future research should focus on the addition of antifibrotics in these patients.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> retrospectively registered<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02094-7","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T04:03:09Z","timestamp":1656129789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis"],"prefix":"10.1186","volume":"23","author":[{"given":"M. C.","family":"Schimmelpennink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. B.","family":"Meek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D. M.","family":"Vorselaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. C. M.","family":"Langezaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. H. M.","family":"van Moorsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"van der Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,25]]},"reference":[{"key":"2094_CR1","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","volume":"357","author":"MC Iannuzzi","year":"2007","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis [Internet]. N Engl J Med. 2007;357:2153.","journal-title":"N Engl J Med"},{"key":"2094_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2020.04.024","volume":"77","author":"M Rubio-Rivas","year":"2020","unstructured":"Rubio-Rivas M, Corbella X. Clinical phenotypes and prediction of chronicity in sarcoidosis using cluster analysis in a prospective cohort of 694 patients. Eur J Intern Med [Internet]. 2020;77:59.","journal-title":"Eur J Intern Med [Internet]."},{"issue":"11","key":"2094_CR3","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1164\/rccm.201010-1679OC","volume":"183","author":"JJ Swigris","year":"2011","unstructured":"Swigris JJ, Olson AL, Huie TJ, Fernandez-Perez ER, Solomon J, Sprunger D, et al. Sarcoidosis-related mortality in the United States from 1988 to 2007. Am J Respir Crit Care Med [Internet]. 2011;183(11):1524\u201330.","journal-title":"Am J Respir Crit Care Med [Internet]."},{"issue":"2","key":"2094_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1378\/chest.14-1120","volume":"147","author":"M Mirsaeidi","year":"2015","unstructured":"Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest. 2015;147(2):438\u201349.","journal-title":"Chest"},{"issue":"6","key":"2094_CR5","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1183\/09031936.00187410","volume":"38","author":"A Nardi","year":"2011","unstructured":"Nardi A, Brillet PY, Letoumelin P, Girard F, Brauner M, Uzunhan Y, et al. Stage IV sarcoidosis: comparison of survival with the general population and causes of death. Eur Respir J [Internet]. 2011;38(6):1368\u201373.","journal-title":"Eur Respir J [Internet]."},{"key":"2094_CR6","doi-asserted-by":"crossref","unstructured":"Jeny F, Uzunhan Y, Lacroix M, Gille T, Brillet PY, Nardi A, et al. Predictors of mortality in fibrosing pulmonary sarcoidosis. Respir Med [Internet]. 2020;169.","DOI":"10.1016\/j.rmed.2020.105997"},{"issue":"1","key":"2094_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","volume":"153","author":"G Kirkil","year":"2018","unstructured":"Kirkil G, Lower EE, Baughman RP. Predictors of mortality in pulmonary sarcoidosis. Chest [Internet]. 2018;153(1):105\u201313.","journal-title":"Chest [Internet]."},{"issue":"18","key":"2094_CR8","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med [Internet]. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med [Internet]."},{"issue":"2","key":"2094_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","volume":"2","author":"SLF Walsh","year":"2014","unstructured":"Walsh SLF, Wells AU, Sverzellati N, Keir GJ, Calandriello L, Antoniou KM, et al. An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study. Lancet Respir Med [Internet]. 2014;2(2):123\u201330.","journal-title":"Lancet Respir Med [Internet]."},{"issue":"6","key":"2094_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1183\/09031936.00166809","volume":"36","author":"PW Boros","year":"2010","unstructured":"Boros PW, Enright PL, Quanjer PH, Borsboom GJJM, Wesolowski SP, Hyatt RE. Impaired lung compliance and DL, CO but no restrictive ventilatory defect in sarcoidosis. Eur Respir J [Internet]. 2010;36(6):1315\u201322.","journal-title":"Eur Respir J [Internet]."},{"key":"2094_CR11","doi-asserted-by":"crossref","unstructured":"Kelley MA, Panettieri RA, Krupinski A V, Philadelphia R. Resting Single-Breath Diffusing Capacity as a Screening Test for Exercise-Induced Hypoxemia. 1986.","DOI":"10.1016\/0002-9343(86)90620-0"},{"key":"2094_CR12","unstructured":"Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, et al. ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis, Vasc Diffus lung Dis Off J WASOG. 1999;16(2):149\u201373."},{"issue":"7","key":"2094_CR13","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1164\/rccm.2111053","volume":"167","author":"AU Wells","year":"2003","unstructured":"Wells AU, Desai SR, Rubens MB, Goh NSL, Cramer D, Nicholson AG, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med [Internet]. 2003;167(7):962\u20139.","journal-title":"Am J Respir Crit Care Med [Internet]."},{"key":"2094_CR14","doi-asserted-by":"crossref","unstructured":"Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N Engl J Med [Internet]. 2015;373(8):782\u2013782.","DOI":"10.1056\/NEJMx150012"},{"issue":"1","key":"2094_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/thoraxjnl-2015-207252","volume":"71","author":"SLF Walsh","year":"2016","unstructured":"Walsh SLF, Calandriello L, Sverzellati N, Wells AU, Hansell DM. Interobserver agreement for the ATS\/ERS\/JRS\/ALAT criteria for a UIP pattern on CT. Thorax [Internet]. 2016;71(1):45\u201351.","journal-title":"Thorax [Internet]."},{"issue":"4","key":"2094_CR16","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/resp.12728","volume":"21","author":"JJ Van Der Vis","year":"2016","unstructured":"Van Der Vis JJ, Snetselaar R, Kazemier KM, Ten Klooster L, Grutters JC, Van Moorsel CHM. Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. Respirology [Internet]. 2016;21(4):712\u20137.","journal-title":"Respirology [Internet]."},{"issue":"6","key":"2094_CR17","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2214\/ajr.174.6.1741751","volume":"174","author":"M Abehsera","year":"2000","unstructured":"Abehsera M, Valeyre D, Grenier P, Jaillet H, Battesti JP, Brauner MW. Sarcoidosis with pulmonary fibrosis: CT patterns and correlation with pulmonary function. Am J Roentgenol. 2000;174(6):1751\u20137.","journal-title":"Am J Roentgenol"},{"key":"2094_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.rmed.2018.04.015","volume":"139","author":"RP Baughman","year":"2018","unstructured":"Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, et al. Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry. Respir Med [Internet]. 2018;139:72\u20138.","journal-title":"Respir Med [Internet]."},{"key":"2094_CR19","doi-asserted-by":"crossref","unstructured":"Chan C, Ryerson CJ, Dunne JV, Wilcox PG. Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulm Med [Internet]. 2019;19(1).","DOI":"10.1186\/s12890-019-0943-2"},{"issue":"4","key":"2094_CR20","first-page":"00094","volume":"5","author":"NA Kampstra","year":"2019","unstructured":"Kampstra NA, van der Nat PB, Dijksman LM, van Beek FT, Culver DA, Baughman RP, et al. Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ Open Res [Internet]. 2019;5(4):00094\u20132019.","journal-title":"ERJ Open Res [Internet]."},{"issue":"22","key":"2094_CR21","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King","year":"2014","unstructured":"King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"22","key":"2094_CR22","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"10","key":"2094_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1159\/000509556","volume":"99","author":"P Faverio","year":"2020","unstructured":"Faverio P, Piluso M, De Giacomi F, Della Zoppa M, Cassandro R, Harari S, et al. Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers. Respiration [Internet]. 2020;99(10):838\u201345.","journal-title":"Respiration [Internet]."},{"issue":"2","key":"2094_CR24","doi-asserted-by":"publisher","first-page":"1902279","DOI":"10.1183\/13993003.02279-2019","volume":"56","author":"J Behr","year":"2020","unstructured":"Behr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J [Internet]. 2020;56(2):1902279.","journal-title":"Eur Respir J [Internet]."},{"issue":"6","key":"2094_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1164\/rccm.200604-520OC","volume":"174","author":"DJ Lederer","year":"2006","unstructured":"Lederer DJ, Arcasoy SM, Wilt JS, D\u2019Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med [Internet]. 2006;174(6):659\u201364.","journal-title":"Am J Respir Crit Care Med [Internet]."},{"key":"2094_CR26","doi-asserted-by":"crossref","unstructured":"Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol [Internet]. 2014;15(1).","DOI":"10.1186\/2050-6511-15-63"},{"key":"2094_CR27","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.rmed.2019.09.001","volume":"157","author":"AJ Gangemi","year":"2019","unstructured":"Gangemi AJ, Myers CN, Zheng M, Brown J, Butler-LeBair M, Cordova F, et al. Mortality for sarcoidosis patients on the transplant wait list in the Lung Allocation Score era: experience from a high volume center. Respir Med [Internet]. 2019;157:69\u201376.","journal-title":"Respir Med [Internet]."},{"issue":"23","key":"2094_CR28","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","volume":"379","author":"P-A Juge","year":"2018","unstructured":"Juge P-A, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease. N Engl J Med [Internet]. 2018;379(23):2209\u201319.","journal-title":"N Engl J Med [Internet]."},{"issue":"5","key":"2094_CR29","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/thoraxjnl-2012-201786","volume":"68","author":"CJ Stock","year":"2013","unstructured":"Stock CJ, Sato H, Fonseca C, Banya WAS, Molyneaux PL, Adamali H, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax [Internet]. 2013;68(5):436\u201341.","journal-title":"Thorax [Internet]."},{"key":"2094_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.clim.2018.12.012","volume":"199","author":"S Tiosano","year":"2019","unstructured":"Tiosano S, Versini M, Dar Antaki L, Spitzer L, Yavne Y, Watad A, et al. The long-term prognostic significance of sarcoidosis-associated pulmonary hypertension\u2014a cohort study. Clin Immunol [Internet]. 2019;199:57\u201361.","journal-title":"Clin Immunol [Internet]."},{"issue":"5","key":"2094_CR31","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1378\/chest.129.5.1246","volume":"129","author":"T Handa","year":"2006","unstructured":"Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M, et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest [Internet]. 2006;129(5):1246\u201352.","journal-title":"Chest [Internet]."},{"key":"2094_CR32","doi-asserted-by":"crossref","unstructured":"Huitema MP, Bakker ALM, Mager JJ, Rensing BJWM, Smits F, Snijder RJ, et al. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study [Internet]. Eur Respir J. NLM (Medline); 2019; 54.","DOI":"10.1183\/13993003.00897-2019"},{"issue":"2","key":"2094_CR33","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1183\/09031936.00175907","volume":"32","author":"JM Bourbonnais","year":"2008","unstructured":"Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J [Internet]. 2008;32(2):296\u2013302.","journal-title":"Eur Respir J [Internet]."},{"issue":"2","key":"2094_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/1817-1737.62471","volume":"5","author":"EH Alhamad","year":"2010","unstructured":"Alhamad EH, Idrees MM, Alanezi MO, Alboukai AA, Shaik SA. Sarcoidosis-associated pulmonary hypertension: clinical features and outcomes in Arab patients. Ann Thorac Med [Internet]. 2010;5(2):86\u201391.","journal-title":"Ann Thorac Med [Internet]."},{"issue":"4","key":"2094_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1752-699X.2008.00120.x","volume":"3","author":"N Milman","year":"2009","unstructured":"Milman N, Svendsen CB, Iversen M, Videb\u00e6k R, Carlsen J. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil. Clin Respir J [Internet]. 2009;3(4):207\u201313.","journal-title":"Clin Respir J [Internet]."},{"issue":"3","key":"2094_CR36","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1378\/chest.128.3.1483","volume":"128","author":"R Sulica","year":"2005","unstructured":"Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest [Internet]. 2005;128(3):1483\u20139.","journal-title":"Chest [Internet]."}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02094-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02094-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02094-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T04:03:15Z","timestamp":1656129795000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02094-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2094"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02094-7","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,25]]},"assertion":[{"value":"12 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Medical research Ethics Committees United (MEC-U) of the St. Antonius Hospital (R05-08A) and all subjects gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"169"}}